Literature DB >> 25716311

Diabetes and ischemic heart disease death in people age 25-54: a multiple-cause-of-death analysis based on over 400 000 deaths from 1990 to 2008 in New York City.

Adriana Quinones1, Iryna Lobach, Gil A Maduro, Nathaniel R Smilowitz, Harmony R Reynolds.   

Abstract

BACKGROUND: Over the past decade, ischemic heart disease (IHD) mortality trends have been less favorable among adults age 25-54 than age ≥55 years. HYPOTHESIS: Disorders associated with IHD such as diabetes, chronic inflammatory and infectious diseases, and cocaine use are important contributors to premature IHD mortality.
METHODS: Multiple-cause-of-death analysis was performed using the New York City (NYC) Vital Statistics database. Frequencies of selected contributing causes on death records with IHD as the underlying cause for decedents age ≥25 were assessed (n = 418,151; 1990-2008). Concurrent Telephone risk-factor surveys (NYC Community Health Survey, Centers for Disease Control Behavioral Risk Factor Survey in New York State) were analyzed.
RESULTS: In sum, a prespecified contributing cause was identified on 13.6% of death certificates for IHD decedents age 25-54. Diabetes was reported more frequently for younger IHD decedents (15% of females and 10% of males age 25-54 vs 6% of both sexes age ≥ 55). In contrast, concurrent diabetes prevalence in New York State was 3.4% for those age 25-54 and 13.6% for those age >55 (P < 0.0001). Systemic lupus erythematosus, human immunodeficiency virus, and cocaine were also more likely to contribute to IHD death among younger than older people.
CONCLUSIONS: Diabetes may be a potent risk factor for IHD death in young people, particularly young women, in whom it was reported on IHD death records at a rate 5× higher than local prevalence. The high frequency of reporting of studied contributing causes in younger IHD decedents may provide a focus for further IHD mortality-reduction efforts in younger adults.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 25716311      PMCID: PMC6711024          DOI: 10.1002/clc.22367

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  4 in total

1.  Cardiovascular Disease Prevention Counseling Program for Systemic Lupus Erythematosus Patients.

Authors:  Cécile M Yelnik; Monica Richey; Virginia Haiduc; Sotiria Everett; Meng Zhang; Doruk Erkan
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-06-26       Impact factor: 4.794

Review 2.  Endothelial function and endothelial progenitor cells in systemic lupus erythematosus.

Authors:  Anselm Mak; Jerry Kok Yen Chan
Journal:  Nat Rev Rheumatol       Date:  2022-04-07       Impact factor: 20.543

3.  Protection of CAPE-pNO2 Against Chronic Myocardial Ischemia by the TGF-Β1/Galectin-3 Pathway In Vivo and In Vitro.

Authors:  Qin Wan; Liwen Zhang; Qidi Zhou; Yanmin Han; Zhubo Li; Boheng Li
Journal:  Inflammation       Date:  2021-11-24       Impact factor: 4.092

4.  mi R -15a/15b Cluster Modulates Survival of Mesenchymal Stem Cells to Improve Its Therapeutic Efficacy of Myocardial Infarction.

Authors:  Yingfeng Tu; Yan Qiu; Li Liu; Tao Huang; Hao Tang; Youbin Liu; Wenguang Guo; Hongchi Jiang; Yuhua Fan; Bo Yu
Journal:  J Am Heart Assoc       Date:  2019-01-08       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.